1. Home
  2. VRAX vs GXAI Comparison

VRAX vs GXAI Comparison

Compare VRAX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • GXAI
  • Stock Information
  • Founded
  • VRAX 2013
  • GXAI 2021
  • Country
  • VRAX United Kingdom
  • GXAI United States
  • Employees
  • VRAX N/A
  • GXAI N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GXAI
  • Sector
  • VRAX Health Care
  • GXAI
  • Exchange
  • VRAX Nasdaq
  • GXAI Nasdaq
  • Market Cap
  • VRAX 7.3M
  • GXAI 7.5M
  • IPO Year
  • VRAX 2022
  • GXAI 2023
  • Fundamental
  • Price
  • VRAX $1.63
  • GXAI $1.53
  • Analyst Decision
  • VRAX
  • GXAI
  • Analyst Count
  • VRAX 0
  • GXAI 0
  • Target Price
  • VRAX N/A
  • GXAI N/A
  • AVG Volume (30 Days)
  • VRAX 253.3K
  • GXAI 707.0K
  • Earning Date
  • VRAX 02-05-2025
  • GXAI 03-26-2025
  • Dividend Yield
  • VRAX N/A
  • GXAI N/A
  • EPS Growth
  • VRAX N/A
  • GXAI N/A
  • EPS
  • VRAX N/A
  • GXAI N/A
  • Revenue
  • VRAX $84,872.00
  • GXAI $2,979.00
  • Revenue This Year
  • VRAX $5,169.18
  • GXAI N/A
  • Revenue Next Year
  • VRAX $66.97
  • GXAI N/A
  • P/E Ratio
  • VRAX N/A
  • GXAI N/A
  • Revenue Growth
  • VRAX 7.03
  • GXAI N/A
  • 52 Week Low
  • VRAX $0.60
  • GXAI $1.01
  • 52 Week High
  • VRAX $9.00
  • GXAI $19.20
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 38.98
  • GXAI 40.09
  • Support Level
  • VRAX $1.58
  • GXAI $1.35
  • Resistance Level
  • VRAX $2.29
  • GXAI $1.66
  • Average True Range (ATR)
  • VRAX 0.22
  • GXAI 0.15
  • MACD
  • VRAX -0.04
  • GXAI -0.01
  • Stochastic Oscillator
  • VRAX 11.77
  • GXAI 19.54

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Share on Social Networks: